Research progress on risk of major adverse cardiovascular events associated with Janus kinase inhibitors in treatment of immune-mediated inflammatory diseases
10.3760/cma.j.cn114015-20240513-00338
- VernacularTitle:Janus激酶抑制剂治疗免疫介导炎症性疾病致主要心血管不良事件的研究进展
- Author:
Danjie ZHAO
1
;
Yuan BIAN
;
Qi'nan YIN
;
Yi WANG
;
Peng TANG
;
Lizhu HAN
Author Information
1. 成都市双流区第一人民医院（四川大学华西空港医院）药学部，成都 610299
- Publication Type:Journal Article
- Keywords:
Janus kinase inhibitors;
Immune-mediated inflammatory disease;
Major adverse cardiovascular events;
Tofacitinib;
Baricitinib;
Ruxolitinib;
Upadacitinib;
Abro
- From:
Adverse Drug Reactions Journal
2025;27(1):44-49
- CountryChina
- Language:Chinese
-
Abstract:
Janus kinase inhibitors (JAKi) are a kind of small molecule targeted drugs used to treat a variety of immune-mediated inflammatory diseases by inhibiting the excessive response of a variety of cytokines. Currently, JAKi has shown good clinical efficacy, but it also has risk of major adverse cardiovascular events (MACE). The specific mechanism of JAKi-caused MACE is still unclear. This paper reviews the pharmacological molecular mechanisms and classification of JAKi and the research progress of MACE related to the JAKi (tolvaptan, baricitinib, ruxolitinib, upadacitinib, and abrocitinib) that have been approved for marketing in China. The risk factors that lead to MACE, including age, combined cardiovascular disease and inflammatory diseases, types of JAKi, dosage forms, and treatment duration are analyzed, so as to provide reference for the clinical rational use of JAKi and better prevention of MACE related to JAKi.
